Altered RU 486 Protocol Increases Risk of
Surgical Intervention
United States use of the abortion pill RU486 was approved by the
pro-abortion administration of President Bill Clinton. But this action,
finalized in 2000, did little more than whet the appetite of the
abortion industry, since there were some strings attached.
At the top of the list of items abortionists have worked unceasingly to
remove were the commonsensical limitations on its use and the attempt
to assure that the two-drug abortion technique is administered in a
manner that decreases the chances that there will be complications for
the mother. (The first drug kills the baby. The second drug-- typically
the prostaglandin misoprostol--stimulates severe uterine contractions
to expel the dead or dying baby.)
For example, the abortion industry didn't like that the protocol put in
place by the Food and Drug Administration (FDA) expected the woman to
come back for separate visits to take each of the drugs in the chemical
cocktail (at least 24-48 hours apart), and which limited the drugs' use
to the first 49 days of pregnancy.
But what happens when women do receive both RU486 and the prostaglandin
simultaneously? It is "not as effective," according to a study just
released by researchers at the Boston Medical Center.
The findings, presented at the 2009 Annual Clinic Meeting of the
American College of Obstetricians and Gynecologists (ACOG) found that
women receiving the drugs simultaneously required "surgical
interventions" (to deal with bleeding, failed abortion, patient
satisfaction) nearly twice as often as those women who observed an
interval of at least a day between the administration of the RU486 and
the prostaglandin (7.4% vs. 3.9%).
Rates of completed abortion after two weeks were 77% for the group
receiving the two drugs simultaneously, and 84% for those taking them
separately. Both completion rates are considerably lower than the 97%
figure advertised by the industry. See, for example, Planned
Parenthood's webpage on the abortion pill at www.plannedparenthood.org.
According to Medscape Medical News (5/5/09), Melissa Stafford, the lead
researcher who presented the findings at the ACOG meeting, indicated
that simultaneous administration was "convenient," according to a
reporter, "because it allowed the physician to confirm that medication
was taken properly" and because "it eliminated the risk of losing
medications."
Unspoken, but obviously a factor to patients, was the "convenience" of
not having to plan a return visit for the second pill.
In the end, Dr. Stafford indicated, the reduced effectiveness was too
big a hurdle for the Boston Medical Center. "We have changed our
practice," she told Medscape, "and we no longer offer simultaneous
administration of mifepristone and misoprostol for medication
abortions."
None of this came as any surprise to pro-life experts who have followed
the twists and turns over the last decade.
"Those who have developed and promoted RU 486 have told women that the
abortifacient offers them a way to have an abortion without the risk of
surgery," says Dr. Randall K. O'Bannon, National Right to Life's
Director of Education and Research.
"But as this latest study shows," he continued, "the abortion
industry's efforts to tamper with the FDA protocol have decreased the
'effectiveness' of these drugs and put many of these women in line for
surgical abortions after their chemical abortions failed."
Almost immediately after the drug combination received government
approval, the abortion industry began to ignore the FDA-prescribed
protocol. They altered the doses-- decreasing the dose of the expensive
RU486 (at one point, priced $90 a pill, three pills to a dose) and
increasing the dosage of the cheap prostaglandin (misoprostol). Rather
than have women return to the office a couple of days later to take the
prostaglandin orally, the clinics gave the women the misoprostol in
their first visit when they came in for the RU486, with instructions to
take the prostaglandin home and vaginally self administer. The ignored
the 49 day limit, prescribing the pills to women at 8 weeks, 9 weeks,
10 weeks or more along in their pregnancy.
Although the industry refused to link the decision, when women began to
die, they pulled back some.
Planned Parenthood, the leader in the abortion industry, announced it
would no longer be recommending the vaginal self administration of the
misoprostol. Their website temporarily reduced time frame it could be
used from 63 to 56 days. (It is back up to 63 now.)
This most recent study shows that the industry continues its efforts to
streamline the process, with all the risks inherent in that.
O'Bannon noted, "Making chemical abortions more 'convenient' for
patients, for abortionists, may help the industry attract more
customers, but it may also have the consequence of making these already
dangerous abortions even more dangerous for women."
He concluded, "As long as the abortion industry puts its own profits
and preferences ahead of patient safety, both mothers and their unborn
children will continue to face danger behind clinic doors."
Contact: Dave Andrusko
Source: National Right to Life
Publish
Date: May 15, 2009
Link
to this article.
Send
this article to a friend.
The IFRL is the largest grassroots pro-life organization in
Illinois. A non-profit organization, that serves as the state
coordinating body for local pro-life chapters representing thousands of
Illinois citizens working to restore respect for all human life in our
society. The IFRL is composed of people of different political
persuasions, various faiths and diverse economic, social and ethnic
backgrounds. Since 1973 the Illinois Federation for Right to Life has
been working to end abortion and restore legal protection to those members of the
human family who are threatened by abortion, infanticide and euthanasia. Diverse though we are, we hold one common belief - that
every human being has an inalienable right to life that is precious and must be protected. IFRL is
dedicated to restoring the right to life to the unborn, and protection
for the disabled and the elderly. Click here to learn more about the IFRL.
|